Delivery Order SPE2DB25D3012-SPE2DB25FWVVC
Award Date
3/3/25
Potential Completion Date
3/4/25
Potential Value
$1.8K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEMABATE 250 MCG/ML AMPULML. The award, valued at $6,555.04, is a firm fixed-price Delivery Order with a completion date of February 16, 2024. This contract does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,431.06 firm fixed-price delivery order is for the supply of HEMABATE 250MCG/ML 10S, a pharmaceutical product, with a completion date of November 5, 2024. The award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,239.50, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract has an ultimate completion date of January 22, 2025 and is a firm fixed-price contract. This contract does not have a set-aside designation, indicating it was competitively awarded....
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,646.59, is for the delivery of HEMABATE 250 MCG/ML AMPULML, a medication used in healthcare settings. The contract has an ultimate completion date of November 19, 2024 and is a Firm Fixed Price Delivery Order. It is not designated as a set-aside contract....
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is for the delivery of HEMABATE 250 MCG/ML AMPULML medication. The $19,035.20 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has a completion date of September 21, 2022. The award is not associated with a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on February 26, 2025 with a ceiling value of $1,695.80. The contract has a firm fixed price pricing type and an ultimate completion date of February 27, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,180.16, is for the supply of HEMABATE 250 MCG/ML AMPULML, a specialty medication. The delivery order has a firm fixed-price pricing type and an ultimate completion date of December 2, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The $1,284.14 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on January 31, 2025, with a completion date of February 3, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a for-profit organization...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,609.63 firm fixed-price delivery order is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a completion date of December 13, 2024. The award is not designated under any specific set-aside program. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,097.24 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract has an ultimate completion date of May 24, 2024 and was awarded on May 23, 2024. It is not set aside for any special designation. Amerisourcebergen, a subsidiary...